Notably, pharmacological blockade of SPHK using N,N-dimethylsphingosine substantially reduces circulating levels of IL-6, TNF-α, and IFN-γ in RA patients, signifying a suppression of systemic inflammatory responses [62]. Here, SPHK1 is linked to rheumatoid arthritis.